Shogo Nakamoto

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 7

Top Topics

Replacement Therapy

Estrogen Receptor

Cross Sectional

Top Venues

Scientific reports

Clinical and experimental medicine

Breast cancer research and treatment

This page only lists publications with an associated author ORCID identifier.

Publications

Shogo Nakamoto, Tadahiko Shien, Takayuki Iwamoto, Shinichiro Kubo, Mari Yamamoto, Tetsumasa Yamashita, Chihiro Kuwahara, Masahiko Ikeda
Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer. Scientific reports 14 (1) (2024)
Shogo Nakamoto, Tadahiko Shien, Takayuki Iwamoto, Shinichiro Kubo, Mari Yamamoto, Tetsumasa Yamashita, Chihiro Kuwahara, Masahiko Ikeda
Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer. Scientific reports 14 (1) (2024)
Shogo Nakamoto, Tadahiko Shien, Mitsuya Itoh, Yutaka Yamamoto, Shozo Ohsumi, Seiji Yoshitomi, Hajime Hikino, Kazuya Miyoshi, Akifumi Notsu, Naruto Taira, Hiroyoshi Doihara, Masahiko Ikeda
Systemic immunity markers are associated with clinical outcomes of atezolizumab treatment in patients with triple-negative advanced breast cancer: a retrospective multicenter observational study. Clinical and experimental medicine (2023)
Shogo Nakamoto, Junichiro Watanabe, Shoichiro Ohtani, Satoshi Morita, Masahiko Ikeda
Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study. BMC cancer 22 (1) (2022)
Junichiro Watanabe, Koichi Mitsuya, Shogo Nakamoto, Hideyuki Harada, Shoichi Deguchi, Nakamasa Hayashi, Yoko Nakasu
Leptomeningeal Metastasis in ER + HER2- Advanced Breast Cancer Patients: A Review of the Cases in a Single Institute Over a 15-year Period. Breast cancer research and treatment 189 (1) (2021)
Shogo Nakamoto, Junichiro Watanabe, Shoichiro Ohtani, Satoshi Morita, Masahiko Ikeda
Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study. Scientific reports 11 (1) (2021)
Shogo Nakamoto, Masahiko Ikeda, Shinichiro Kubo, Mari Yamamoto, Tetsumasa Yamashita, Akifumi Notsu
Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer. Scientific reports 11 (1) (2021)